GLT8D2 and metabolic dysfunction-associated steatotic liver disease: Based on these results, we conclude that the impairment of MTP function by GLT8D2 is attributed to the enhanced accumulation of triglyceride in hepatocytes during development of NAFLD, and specific inhibition of GLT8D2 via an antagonistic strategy could provide a potential candidate approach for treatment of NAFLD.